Aims and scope
The Journal of Thrombosis and Thrombolysis is a long-awaited resource for contemporary cardiologists, hematologists, vascular medicine specialists and clinician-scientists actively involved in treatment decisions and clinical investigation of thrombotic disorders involving the cardiovascular and cerebrovascular systems. The principal focus of the Journal centers on the pathobiology of thrombosis and vascular disorders and the use of anticoagulants, platelet antagonists, cell-based therapies and interventions in scientific investigation, clinical-translational research, population science and patient care. In keeping with our commitment to contemporary topics and scientific advance on a global scale, the Journal has established a section dedicated to the COVID-19 pandemic with an accelerated peer review, decision, and publication of scholarly review papers, observational studies and randomized clinical trials that will inform scientific undertakings and patient management.
The Journal will publish original work which emphasizes the interface between fundamental scientific principles and clinical investigation, stimulating an interdisciplinary and scholarly dialogue in thrombosis and vascular medicine. Published works will also define platforms for translational research, drug development, clinical trials, new drugs and devices, and patient-directed applications. The Journal of Thrombosis and Thrombolysis' integrated format will expand the reader's knowledge base and provide important insights for both the investigation and direct clinical application of the most rapidly growing fields in medicine-thrombosis and vascular medicine.
The Journal seeks original manuscripts devoted to fundamental science in cardiovascular disease, laboratory investigation, pharmacogenetics, clinical research, global health, population science, and epidemiology. State-of-the-art reviews, position papers and editorials will be summoned by invitation from the editor or an appointed guest editor. The Journal will publish special issues and supplements from national and international symposia and scientific committees in a timely fashion by working closely with organizers and contributing authors.
Manuscripts submitted must not be under consideration by another journal and should not have been published elsewhere in similar form. All articles will be reviewed by a minimum of two highly qualified referees. All clinical trials being considered for publication will also be reviewed by a statistician. A response will be provided within 2-3 weeks of receipt.